Balaglitazone

Balaglitazone is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma, EC50 = 1.351 µM in a transactivation assay). It decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day). Balaglitazone (5 and 10 mg/kg per day) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats. In doxorubicin-resistant K562 human myelogenous leukemia cells, balaglitazone (25 µM) decreases P-glycoprotein (P-gp) levels, increases intracellular accumulation of the P-gp substrate rhodamine 123 (Cay-16672), and sensitizes cells to doxorubicin (Cay-15007).Formal Name: 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione. CAS Number: 199113-98-9. Synonyms: DRF 2593. Molecular Formula: C20H17N3O4S. Formula Weight: 395.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml. lambdamax: 226 nm. SMILES: O=C1N(C)C(COC2=CC=C(CC3SC(NC3=O)=O)C=C2)=NC4=CC=CC=C41. InChi Code: InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26). InChi Key: IETKPTYAGKZLKY-UHFFFAOYSA-N.